Suchergebnisse - "Guaraldi, Giovanni"

PubPharm (65)

1

The best place for doravirine

enthalten in: The lancet. HIV | 2024

von Mussini, C. | Guaraldi, G.

ErratumIn: Lancet HIV. 2024 Mar 28;:. - PMID 38555921

2

Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023

enthalten in: HIV medicine | 2023

von Ambrosioni, J. | Levi, L. | Alagaratnam, J. | +18

3

Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von González-Cordón, A. | Assoumou, L. | Moyle, G. | +117

4

Comparing implications of cardiovascular risk of abacavir and integrase inhibitors : why scientific community is confused and timid?

enthalten in: AIDS (London, England) | 2023

von Guaraldi, G. | Milic, J.

5

BEING : Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal Period

enthalten in: AIDS research and human retroviruses | 2023

von Walmsley, S. | Clarke, R. | Lee, T. | +7

6

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk : A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Waters, L. | Assoumou, L. | González-Cordón, A. | +121

7

Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021

enthalten in: HIV medicine | 2022

von Ryom, L. | De Miguel, R. | Cotter, A. | +19

8

Switch back from TAF to TDF or rather switch forward from metabolic toxicities of drugs to metabolic health of people living with HIV

enthalten in: AIDS (London, England) | 2022

von Stapleton, J. | Bedimo, R. | Guaraldi, G.

CommentOn: AIDS. 2022 Aug 1;36(10):1337-1344. - PMID 35727143

9

Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir : a substudy of the NEAT022 study

enthalten in: The Journal of antimicrobial chemotherapy | 2022

von Saumoy, M. | Sánchez-Quesada, J. | Assoumou, L. | +12

10

Re : "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir" by Calza et al

enthalten in: AIDS research and human retroviruses | 2021

von Ciccullo, A. | Baldin, G. | Borghi, V. | +5

CommentOn: AIDS Res Hum Retroviruses. 2021 Mar;37(3):204-206. - PMID 33126811

1
2
3
4
5
6
7
Nächster »
[7]